GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Institutional Ownership

Sino Biopharmaceutical (HKSE:01177) Institutional Ownership : 17.26% (As of May. 01, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sino Biopharmaceutical's institutional ownership is 17.26%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sino Biopharmaceutical's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sino Biopharmaceutical's Float Percentage Of Total Shares Outstanding is 0.00%.

Sino Biopharmaceutical Institutional Ownership Historical Data

The historical data trend for Sino Biopharmaceutical's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Institutional Ownership Chart

Sino Biopharmaceutical Historical Data

The historical data trend for Sino Biopharmaceutical can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 14.43 14.48 14.14 13.58 13.40 13.73 16.92 16.91 17.16 17.26

Sino Biopharmaceutical Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Sino Biopharmaceutical (HKSE:01177) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Institutional Ownership
Comparable Companies
HKSE:02269 HKSE:01801 HKSE:09926 HKSE:06990 HKSE:01877 HKSE:09995 HKSE:01548 HKSE:06826 HKSE:01530 HKSE:06660 OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
SBHMY:USA SBMFF:USA SMZ1:Germany
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Website
https://www.sinobiopharm.com
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines